Fig. 4.

The role of IL-17A on in vivo implanted 4T1 cells in BALB/c mice. Three groups of 4T1–bearing BALB/c mice were designed, namely wild type (WT), ΔIL-17A, and WT + neutralizing IL-17 antibody (WT + Ab). After tumor cells were implanted. Neutralizing IL-17A antibody (250 μg/100μL) was injected, twice a week, intraperitoneally in WT + Ab group. After 3 weeks of tumor cells implantation, animals were sacrificed under adequate anesthetized. Tumor volume curve and necrosis area were photographed and measured (a). Immunohistochemistry and Western blot for CD34 expression were quantified (b). Bar indicated 50 μm. Asterisk indicates a p value < 0.05, Mann–Whitney U test